because rigorously controlled human safety data specific to the TB-500 fragment does not exist, its longer-term risk profile, including possible immune reactions, remains unknown Evidence snapshot: Evidence for TB-500 itself is preclinical, drawn mainly from cell-culture and animal studies (a 1999 rat wound-healing study and later rodent cardiac- and tendon-injury models), with a 2026 scoping review describing the musculoskeletal literature on thymosin beta-4 and TB-500 as sparse and largely preclinical
Researchers study NAD in work involving energy metabolism, mitochondrial function, and enzymatic pathways such as sirtuins and PARPs
balancing work, commuting, and parenting without quitting training switching from lunch-hour workouts to a consistent 5 a.m
Take a minimum 2-week break
10.1111/j.1476-5381.1996.tb15280.x Br
TB 500 is used in a variety of medical and performance-related treatments